JPS6257165B2 - - Google Patents
Info
- Publication number
- JPS6257165B2 JPS6257165B2 JP55094258A JP9425880A JPS6257165B2 JP S6257165 B2 JPS6257165 B2 JP S6257165B2 JP 55094258 A JP55094258 A JP 55094258A JP 9425880 A JP9425880 A JP 9425880A JP S6257165 B2 JPS6257165 B2 JP S6257165B2
- Authority
- JP
- Japan
- Prior art keywords
- fluorouridine
- dideoxy
- uracil
- antitumor
- antitumor effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims description 40
- 230000000259 anti-tumor effect Effects 0.000 claims description 26
- 229940035893 uracil Drugs 0.000 claims description 20
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 16
- 239000003623 enhancer Substances 0.000 claims description 9
- 229940113082 thymine Drugs 0.000 claims description 8
- FHIDNBAQOFJWCA-UAKXSSHOSA-N 5-fluorouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 FHIDNBAQOFJWCA-UAKXSSHOSA-N 0.000 claims description 5
- 230000002708 enhancing effect Effects 0.000 claims description 2
- GJPQKIQISJHKEA-PRMYIZFSSA-N 5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](C)O[C@H]1N1C(=O)NC(=O)C(F)=C1 GJPQKIQISJHKEA-PRMYIZFSSA-N 0.000 description 21
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000002246 antineoplastic agent Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000006268 Sarcoma 180 Diseases 0.000 description 2
- 241000978776 Senegalia senegal Species 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- KZEVSDGEBAJOTK-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[5-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CC=1OC(=NN=1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O KZEVSDGEBAJOTK-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9425880A JPS5718618A (en) | 1980-07-09 | 1980-07-09 | Antitumor agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9425880A JPS5718618A (en) | 1980-07-09 | 1980-07-09 | Antitumor agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5718618A JPS5718618A (en) | 1982-01-30 |
| JPS6257165B2 true JPS6257165B2 (fr) | 1987-11-30 |
Family
ID=14105254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9425880A Granted JPS5718618A (en) | 1980-07-09 | 1980-07-09 | Antitumor agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5718618A (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63308563A (ja) * | 1987-06-10 | 1988-12-15 | Honda Motor Co Ltd | エンジン回転計駆動装置 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6092217A (ja) * | 1983-10-26 | 1985-05-23 | Funai Corp | フルオロデオキシウリジン誘導体とチミジンとを含有する抗腫瘍剤 |
| US4997818A (en) * | 1987-09-21 | 1991-03-05 | The University Hospital | Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS484476U (fr) * | 1971-06-14 | 1973-01-19 | ||
| JPS5746561A (en) * | 1980-09-04 | 1982-03-17 | Mitsubishi Electric Corp | Fsk demodulating circuit |
-
1980
- 1980-07-09 JP JP9425880A patent/JPS5718618A/ja active Granted
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS484476U (fr) * | 1971-06-14 | 1973-01-19 | ||
| JPS5746561A (en) * | 1980-09-04 | 1982-03-17 | Mitsubishi Electric Corp | Fsk demodulating circuit |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63308563A (ja) * | 1987-06-10 | 1988-12-15 | Honda Motor Co Ltd | エンジン回転計駆動装置 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5718618A (en) | 1982-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7589084B2 (en) | Anticancer compositions, and methods of making and using the same | |
| US5036103A (en) | Method of treating cancer cells in humans | |
| CA2640509C (fr) | Utilisation de complexes de gallium (iii) pour le traitement de melanomes | |
| US4622325A (en) | Anti-cancer composition for delivering 5-fluorouracil | |
| WO2004081012A1 (fr) | Potentialisateur de l'effet antitumoral et agent antitumoral | |
| JP2688057B2 (ja) | 抗腺がん剤 | |
| JP2557303B2 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| KR100310121B1 (ko) | 티아조푸린및리바비린을사용하는종양질환의치료방법 | |
| JPS6257165B2 (fr) | ||
| JP3982889B2 (ja) | イブプロフェン含有医薬製剤 | |
| JPH07116031B2 (ja) | 制癌剤 | |
| US4719213A (en) | Anti-cancer composition for delivering 5-fluorouracil | |
| TW201513870A (zh) | 含伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| JPH0120128B2 (fr) | ||
| JPS621371B2 (fr) | ||
| JPS6312845B2 (fr) | ||
| JPS6213924B2 (fr) | ||
| JPS6231689B2 (fr) | ||
| JPS6183125A (ja) | 癌転移阻害剤 | |
| US4006235A (en) | Treating CNS lymphoma | |
| US4005204A (en) | Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine | |
| JPS6223725B2 (fr) | ||
| JPS6337767B2 (fr) | ||
| JPS6223723B2 (fr) | ||
| JPS6231690B2 (fr) |